You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Pergolide reduced involuntary periodic leg movements and improved sleep in the restless legs syndrome

https://doi.org/10.1136/ebm.5.1.21

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (1999) Neurology 52, 944. Wetter TC, Stiasny K, Winkelmann J, et al.. A randomized controlled study of pergolide in patients with restless legs syndrome.. Mar;. :. –50..
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In patients with idiopathic restless legs syndrome (RLS), is pergolide effective for improving symptoms and sleep?

    Design

    12-week randomised (allocation concealed*

    Setting

    Outpatient clinic for movement and sleep disorders in Germany.

    Patients

    Patients were 28–70 years of age and had an irresistible urge to move that was related to sensory symptoms of the lower limbs; motor restlessness; worsening of symptoms at rest with some relief found through activity; increased symptom severity in the evening or at night; abnormal periodic leg movement (PLM) index; sleep-onset latency >25 minutes or sleep efficiency <85%; and normal values for serum chemistry and urinalysis. Exclusion criteria were secondary RLS, other primary sleep disorders, history of substance abuse, pregnancy, lactation, hypersensitivity to ergot derivatives, current antihistamine use, serious medical conditions, or current diagnosis or history of malignant melanoma. 30 patients were enrolled, and 28 (93%, mean age 57 y, 57% women) were …

    View Full Text

    Footnotes

    • Source of funding: Lilly Deutschland GmbH. Drugs provided by Eli Lilly and Company.

    • For correspondence: Dr T C Wetter, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D-80804 Munich, Germany. FAX +49-89-30622-550.

    • ↵* See glossary.), double-blind, placebo-controlled crossover trial.